Rheumatoid Arthritis Clinical Trial
— DISRUPT-estRAOfficial title:
Effect of Controlling Environmental Risk Factors in Established RA
- The factors contributing to the development of rheumatoid arthritis are multiple, with a role of the environment and a predisposing genetic background. - Among the modifiable environmental factors :unbalanced diet, overweight, low physical activity, smoking, periodontal disease, stress have been identified as risk factors for developing RA. - By causing low-grade inflammation and stimulation of the immune system (particularly through adipokines, citrullination phenomena and changes in the microbiota), these factors promote the onset of the disease and could also participate in the maintenance of inflammatory processes. - Thus, obese subjects have more active RA, a lower therapeutic response, and weight loss is associated with lower disease activity ; sedentary lifestyle is associated with more active RA and increased physical activity has beneficial effects on RA; people who smoke respond less well to treatment; periodontal disease is associated with more active RA and their treatment is associated with a decrease in this activity. - Finally, different methods having a beneficial impact on stress (mindfulness meditation, yoga, relaxation, etc.) have shown interesting results in patients with RA. - It is important to note that all of these factors are also associated with an increased cardiovascular risk, the leading cause of death in RA. - The combination of these factors probably has synergistic effects and it is therefore relevant to propose a correction of all these factors in the same program. - We have developed a management program for environmental risk factors for RA based with experts including rheumatologists, nutritionists, smoking cessation specialists, periodontal disease specialists and stress specialists.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | January 2025 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - RA (ACR / EULAR 2010 criteria), with an active disease (2.6 <DAS 28 <5.1) - Basis treatment for at least 3 months and corticoids <= 10mg / day And at least 3 risk factors among: - BMI =25 kg / m² - Low physical activity (IPAQ short version) - Active smoking - Periodontitis ( bone loss on dental panoramic) - Anxiety ( Beck anxiety Index > 16) Exclusion Criteria: - Patient under protective measure or unable to consent - Patient for whom a change in basic treatment for RA is planned within 6 months - Active cancer - Active infection - Antibiotic therapy in the previous 3 months - No health cover - Diabetes - Unbalanced psychiatric pathologies - Pregnant or breastfeeding women |
Country | Name | City | State |
---|---|---|---|
France | Centre Hospitalier Universitaire de Montpellier | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimate the effectiveness at 6 months of this program on the overall reduction / correction of risk factors. | Number of patients for whom at least 2 or 3 risk factors (depending on whether 3 present or 4-5 present at baseline) are corrected / in the process of correction.
Risk factors will be considered corrected / in the process of being corrected if: Weight loss =5% of initial weight at 6 months (objective measurement of weight) and / or BMI at 6 months < 25kg/m² Complete smoking cessation (declarative assessment) Correction of sedentary lifestyle with moderate to strong IPAQ AND increase of =2,000 steps / day compared to the initial assessment (on average 5 days / 7) (questionnaire and quantified assessment obtained with the pedometer and automatically reported on the platform) Improvement in periodontal disease scores =4 points on 6 teeth assessed according to Ramfjord's recommendation (plaque index (Sillness and Loe index), gingival (Lobene index) and papillary bleeding index) (evaluation by the periodontologist) Decrease in anxiety score from N class to N-1 class |
6 MONTHS | |
Secondary | To assess the acceptability and adherence of RA patients to the intervention program. | Acceptability:
number of patients agreeing to participate in the protocol / total number of screened patients fulfilling the inclusion criteria. questionnaire with different visual analog scales carried out at the end of the program. Adherence: assessed by completing online questionnaires / weight, using the accelerometer, participating in various teleconsultations and organized group sessions |
6 MONTHS | |
Secondary | At least two risk factors (if 3 present at base) or at least three (if 4 or 5 present at base) are corrected / in the process of correction. | same description as for the outcome 1 | 3 MONTHS | |
Secondary | RA activity | DAS 28-CRP, RAID, biological markers (FR, ACPA, CRP) | 3 MONTHS, 6 MONTHS | |
Secondary | Distribution of the different germs of the oral and fecal micobiota and alpha and beta diversity | targeted metagenomics 16s RNA | 3 MONTHS, 6 MONTHS | |
Secondary | Personality traits assessed by the Minnesota Multiphasic Personality Inventory questionnaire (MMPI) | MONTH 0 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |